(PharmaNewsWire.Com, May 19, 2021 ) Growth in the sleep apnea devices market can be attributed to factors such as a large pool of undiagnosed sleep apnea patients, growing awareness about the ill effects of untreated sleep apnea, growing usage of oral appliances, technological advancements in sleep apnea devices, influx of venture capital funding, and the increasing number of companies venturing into sleep apnea and oral appliances markets.
Also, there are growth opportunities for the market due to the increasing demand for home healthcare and increasing focus on telemedicine and mHealth (mobile Health). On the other hand, the high cost of CPAP machines and complex referral pathways & long waiting periods are expected to be the key factors that restrain market growth to a certain extent during the forecast year.
The major players in the sleep apnea devices market include ResMed (US), Koninklijke Philips (Netherlands), and Fisher & Paykel Healthcare (New Zealand). Analysis of the market developments between 2016 and 2019 revealed that several growth strategies such as partnerships & agreements, expansions, service launches, and strategic acquisitions were adopted by the market players to strengthen their product portfolios and maintain a competitive position in the sleep apnea devices market.
In 2018, ResMed (US) dominated the sleep apnea devices market. The company has a diversified product portfolio, widespread geographical presence, and focuses on strategies such as product launches and innovations. The company also focuses on launching technologically advanced products in order to maintain its leading position in the market. Additionally, ResMed has a broad product portfolio for sleep apnea disorders and offers a variety of devices and accessories. The company prominently operates in the Americas. It pursues business strategies such as product launches, approvals, enhancements, and acquisitions in order to sustain its position in the sleep apnea devices market. For instance, in 2019, ResMed launched the AirFit N30i, its first top-of-head-connected nasal CPAP mask. In 2018, ResMed upgraded its Astral life support ventilators, including its Optional AutoEPAP in iVAPS. In 2018, ResMed launched its QuietAir Diffuser Vent for CPAP masks, AirFit F20 with silicone cushion, and its AirTouch F20 with memory foam cushion. In 2019, ResMed acquired HB Healthcare, a home medical equipment provider, which offers sleep and respiratory care devices. Through this acquisition, ResMed extended its reach to patients through HBH and its wider network of trusted distributor partners.
In 2018, Koninklijke Philips (Netherlands) was the second largest player with a share of ~39%. The company’s wide geographical presence and strong distribution network have also helped it gain a significant market share. In the past three years, innovation has been the company’s core business strategy in order to increase its share in the sleep apnea devices market. This strategy is largely supported by the company’s strong R&D activities. Philips invested USD 2.07 billion in R&D activities in 2017. Philips’ rich pool of skilled R&D personnel ensures constant development and launch of technologically advanced products in the sleep apnea devices market. This further helps the company in launching products like masks, PAP devices, and ventilators in the market.
In 2018, Fisher & Paykel Healthcare (New Zealand) was the third largest player with a share of ~13%. The company employs multiple distribution channels to market its products in more than 120 countries. It employs a direct sales team in around 36 countries to sell its products directly to hospitals, long-term care facilities, and home healthcare dealers. The direct sales team enables the firm to have a dedicated focus on its products, rather than being present in the distributor’s portfolio with other companies.
The company invested 9.0%, 9.6%, and 9.7 % of its total revenue in 2015, 2016, and 2017, respectively, into R&D activities and introduced about five new products in the same period. Fisher & Paykel’s rich pool of skilled R&D personnel ensures constant development and introduction of technologically advanced products in the market.
MarketsandMarkets™ provides quantified B2B research on 30,000 high growth niche opportunities/threats which will impact 70% to 80% of worldwide companies’ revenues. Currently servicing 7500 customers worldwide including 80% of global Fortune 1000 companies as clients. Almost 75,000 top officers across eight industries worldwide approach MarketsandMarkets™ for their painpoints around revenues decisions.
Our 850 fulltime analyst and SMEs at MarketsandMarkets™ are tracking global high growth markets following the "Growth Engagement Model – GEM". The GEM aims at proactive collaboration with the clients to identify new opportunities, identify most important customers, write "Attack, avoid and defend" strategies, identify sources of incremental revenues for both the company and its competitors. MarketsandMarkets™ now coming up with 1,500 MicroQuadrants (Positioning top players across leaders, emerging companies, innovators, strategic players) annually in high growth emerging segments. MarketsandMarkets™ is determined to benefit more than 10,000 companies this year for their revenue planning and help them take their innovations/disruptions early to the market by providing them research ahead of the curve.
MarketsandMarkets’s flagship competitive intelligence and market research platform, "Knowledgestore" connects over 200,000 markets and entire value chains for deeper understanding of the unmet insights along with market sizing and forecasts of niche markets.
We are pleased to offer you this exciting, new, and entirely free professional resource. Visit our Free Biotechnology & Pharmaceuticals resource center today to browse our selection of 600+ complimentary Biotechnology & Pharmaceuticals magazines, white papers, webinars, podcasts, and more. Get popular titles including:
